Clinical Trial

Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy

Study acronym: REaCT-OGF
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this randomized, pragmatic clinical trial is to evaluate the omission of granulocyte colony-stimulating factors (G-CSF) in breast cancer patients receiving paclitaxel portion of dose-dense adriamycin-cyclophosphamide and paclitaxel (DD-AC/T) chemotherapy. Participants will be randomized to either take G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy or to omit G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-02-22; most recent amendment 2026-07-06.
Status change: Not Yet Recruiting → Recruiting 2023-04-20
Trial Details
NCT Number NCT05753618
Lead Sponsor Ottawa Hospital Research Institute
Conditions Early-stage Breast Cancer
Enrollment 242 participants
Start Date 2023-04-17
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-08